AML Arising After Exposure to Genotoxic Injury Active Not Recruiting Phase 1 Trials for Enasidenib (DB13874)

IndicationStatusPhase
DBCOND0076146 (AML Arising After Exposure to Genotoxic Injury)Active Not Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02632708Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia With an IDH1 and/or IDH2 MutationTreatment